Merrimack Pharmaceuticals Inc. won the FDA's approval on Oct. 22 to market Onivyde (irinotecan liposome injection), an topoisomerase inhibitor, as a treatment in combination with fluorouracil (5-FU) and leucovorin for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Merrimack Pharmaceuticals Inc. won the FDA's approval on Oct. 22 to market Onivyde (irinotecan liposome injection), an topoisomerase inhibitor, as a treatment in combination with fluorouracil (5-FU) and leucovorin for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Andrea Wang-Gillam, an associate professor of medicine and clinical director of GI oncology at the Washington University School of Medicine...
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Series B cash will be used to advance its Stargardt disease gene therapy.
